Trial Profile

Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ME 344 (Primary)
Indications Carcinoid tumour; Cervical cancer; Leiomyosarcoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Urogenital cancer; Uterine cancer
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Lite Strategy; MEI Pharma

Most Recent Events

10 Sep 2025 According to MEI Pharma media release, MEI Pharma has changed its name to Lite Strategy.
04 May 2015 Results published in Cancer, according to a MEI Pharma media release.
04 May 2015 Status changed from active, no longer recruiting to completed, according to a MEI Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com